Kalaris Therapeutics, Inc. (KLRS)

NGM – Real Time Price. Currency in USD

4.79

+0.06 (1.27%)

At close: May 12, 2026, 4:00 PM EDT

4.79

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

17.03.2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

19.12.2025

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a data showed a clinically significant 10-letter visual acuity gain and promising durability, with 31% of patients needing no rescue injection for six months. With $77M in cash and a quarterly burn of ~$12M, KLRS is funded through 2027, enabling execution through the critical Phase 1b/2 data readout expected in H2 2026.

18.12.2025

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS's lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26.

17.12.2025

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses.

17.12.2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection

24.11.2025

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference. Details: Type: Company presentation Speakers: Matthew Feinsod, Chief Medical Officer Date: Wednesday, December 3, 2025 Time: 11:30 - 11:55 am ET Location: Florida Atlantic University, Boca Raton, FL Kalaris management will be available for one-on-one meetings during the conference.

12.11.2025

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026 Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to fund operations into 2027 Kalaris is currently evaluating TH103, a dual-targeting biologic designed to achieve superior VEGF inhibition and extended intraocular durability through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the third quarter ended September 30, 2025, and provided business updates.

Videos

No Data

There is no data to display

Press releases

17.03.2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

17.12.2025

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

17.12.2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection

12.11.2025

Kalaris Therapeutics, Inc. (KLRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kalaris Therapeutics, Inc. (KLRS)

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Search stocks

Kalaris Therapeutics, Inc. (KLRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kalaris Therapeutics, Inc. (KLRS)

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates